

Multi-residue veterinary drug analysis of >200 compounds using MRM Spectrum mode by LC-MS/MS

ASMS 2017 TP-207

David Baker¹, Laetitia Fages², Eric Capodanno²,
Neil Loftus¹

¹Shimadzu, Manchester, UK

²Phytocontrol, Nimes, France

Multi-residue veterinary drug analysis of >200 compounds using MRM Spectrum mode by LC-MS/MS

Introduction

Veterinary drugs are used for therapeutic, metaphylactic, prophylactic and growth promotion purposes. To provide an assurance that food from animals is safe with regards to residues of veterinary medicines, regulatory authorities have established Maximum Residue Limits (MRL's) for certain drugs in target tissues and animal species and has also identified pharmacologically active compounds that are prohibited and considered a hazard at any level (EU regulation EC 37/2010; Commission Decision 2003/181/EC; 21CFR Part 556 Tolerances for Residues of

New Animal Drugs in Food). In this work, we describe a method that delivers highly sensitive and selective triple quadrupole detection together with MRM Spectrum mode to reduce false positive and false negative reporting. MRM Spectrum mode acquires a high number of fragment ion transitions for each target compound generating a fragmentation spectra that could be used in routine library searching and compound verification using reference library match scores.

Materials and Methods

Samples of beef, egg, honey, milk and salmon were extracted and spiked in the calibration range 0.001 – 0.1 mg/kg. Repeatability was assessed at low and high concentrations. Samples were measured using a Nexera

UHPLC and the LCMS-8060 triple quadrupole detector (Table 1). Over 200 veterinary drugs were targeted, with more than 2,000 MRM transitions in both ESI +/- during the 12minute gradient.

Table 1. LC and MS/MS acquisition parameters used to create the LC-MS/MS method.

Liquid chromatography													
UHPLC	: Nexera LC system												
Analytical column	: Restek Biphenyl (100 x 2.1, 2.7µm)												
Column temperature / Flow rate	: 40°C ; 0.4mL/minute												
Solvent A	: 0.1% formic acid 0.5mM ammonium formate solution												
Solvent B	: 0.1% formic acid in methanol												
Binary Gradient	: <table border="1" data-bbox="578 1449 979 1676"> <thead> <tr> <th>Time (mins)</th> <th>%B</th> </tr> </thead> <tbody> <tr> <td>0.00</td> <td>2</td> </tr> <tr> <td>12.50</td> <td>100</td> </tr> <tr> <td>14.50</td> <td>100</td> </tr> <tr> <td>14.60</td> <td>2</td> </tr> <tr> <td>17.50</td> <td>Stop</td> </tr> </tbody> </table>	Time (mins)	%B	0.00	2	12.50	100	14.50	100	14.60	2	17.50	Stop
Time (mins)	%B												
0.00	2												
12.50	100												
14.50	100												
14.60	2												
17.50	Stop												
Mass spectrometry													
Mass spectrometer	: Shimadzu LCMS-8060												
Pause time/dwell time	: 1 msec/3 msec												
Polarity switching time	: Pos/neg switching time set to 5 msec												
Scope	: 218 drugs in positive ion mode (including internal standards) 11 drugs in negative ion mode Structure Analytics (in house development tool)												
Source temperatures (interface; heat block; DL)	: 350°C; 300°C; 150°C												
Gas flows (nebulising; heating; drying)	: 3L/min; 10 L/min; 10L/min												



Multi-residue veterinary drug analysis of >200 compounds using MRM Spectrum mode by LC-MS/MS

Advantages of MRM Spectrum mode

The method is straightforward to set-up using conventional MRM optimization procedures and acquisition windows (scheduled MRM) resulting in high data densities and a high data sampling rate across a peak. This approach generates a consistent loop time and sampling rate producing reliable quantitation and peak

integration. It also enables greater flexibility in routine veterinary drug monitoring programs by supporting a change in the qualifier and quantifier ion selection. The number of precursor-fragment ion transitions used to generate a product ion spectrum is only limited by the chemical structure of the veterinary drug.

Results



MRM Spectrum mode
 Higher specificity
 Higher reporting confidence
 Library searchable fragment data.

The number of precursor-fragment ion transitions monitored is limited only by the structural chemistry of the molecule. Typically more than 10 precursor-fragment ion transitions were monitored for each veterinary drug.

Figure 1. MRM Spectrum mode was used to acquire a high number of fragment ions for each veterinary drug target. For chlortetracycline, 11 precursor-fragment ion transitions were acquired using optimized collision energies. By acquiring a high number of fragment ion transitions, each target veterinary drug had a corresponding fragmentation spectra which could be used in routine library searching and compound verification using reference library match scores. (Chlortetracycline is a tetracycline class of antimicrobial. According to the Sixth ESVAC report published in 2016, of the overall sales of antimicrobials in the 29 EU countries in 2014, the largest amounts, expressed as a proportion of mg/PCU, were accounted for by tetracyclines (33.4 %), penicillins (25.5%) and sulfonamides (11.0 %). Chlortetracycline was selected as a representative target).

Multi-residue veterinary drug analysis of >200 compounds using MRM Spectrum mode by LC-MS/MS




Figure 2. MRM reference spectrum for chlortetracycline with assigned fragment structures. MRM Spectrum mode combines MRM with the generation of a product ion spectrum. The product ion spectrum can be used for compound identification by searching a library. As the collision energy was optimized for each fragment ion to generate a product ion spectrum, the library spectrum is highly specific and selective. (Each precursor-fragment ion transitions structure may be verified by using Structure Analytics to show commonly described losses and charge migration; the hydrogen deficit is shown in brackets).

Library identification using MRM Spectrum mode





Figure 3. Library searchable MRM spectrum data for chlortetracycline in different matrices spiked at 10pg/uL.

Multi-residue veterinary drug analysis of >200 compounds using MRM Spectrum mode by LC-MS/MS



Compound name	Oxytetracycline		Sulfadimethoxine		Ormetoprim		Virginiamycin	
Number of MRM's	2MRM's	8MRMs	2MRM's	11MRMs	2MRM's	11MRMs	2MRM's	11MRMs
Mean peak area Quantitation ion	1890170	1729171	7809989	7227748	8291171	8160952	2232967	1956045
%RSD	3.74	3.04	1.49	1.46	1.54	1.18	0.91	1.65




Figure 4. Virginiamycin S1 was spiked into an extract of salmon at a concentration of 10pg/uL and repeatedly injected (n=10). The library score was above 99 in all injections (injection 1, 5 and 10 shown above) using 11 MRM's to generate a product ion spectrum (Structure Analytics was used to propose fragment structures; the hydrogen deficit is shown in brackets). %RSD for oxytetracycline, sulfadimethoxine, ormetoprim, and virginiamycin spiked into salmon (n=10; 10pg/uL) acquired using a conventional 2 MRM method compared to a MRM spectrum method with a higher number of fragment ions. [Compound selection based on antibiotics used in aquaculture; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254636/>].

Multi-residue veterinary drug analysis of >200 compounds using MRM Spectrum mode by LC-MS/MS


Quantitation using MRM Spectrum mode

To assess the robustness of this approach the same sample was repeatedly injected using a method that compiled with the identification criteria set out in the EU guidelines SANTE/11945/2015 that requires the retention time and the ion ratio from at least 2 MRM transitions to

be within acceptable tolerance limits. The absolute response and signal variability was compared to a method using a higher number of fragment ions (Table 2). Both methods resulted in a variance of less than 4%RSD (n=10 for each method; 10pg/uL spiked into salmon matrix).



Compound name Sulfamerazine
Precursor 265.10 [M+H]⁺
Formula C₁₁H₁₂N₄O₂S
CAS 127-79-7



MRM Spectrum Mode
11 MRM's acquired for sulfamerazine in beef.

- 1:265.10>156.05 (+) CE : -17V
- 2:265.10>92.05 (+) CE : -30V
- 3:265.10>172.05 (+) CE : -15V
- 4:265.10>108.05 (+) CE : -26V
- 5:265.10>65.00 (+) CE : -11V
- 6:265.10>110.05 (+) CE : -22V
- 7:265.10>80.05 (+) CE : -15V
- 8:265.10>38.95 (+) CE : -14V
- 9:265.10>199.10 (+) CE : -21V
- 10:265.10>93.10 (+) CE : -30V
- 11:265.10>66.05 (+) CE : -24V




Figure 5. Library searchable MRM spectrum data for sulfamerazine over three orders of magnitude (1pg/uL to 100pg/uL). Linear calibration curves were generated for all compounds with r2 typically greater than 0.9996. Sulfamerazine was selected as a representative target.

Multi-residue veterinary drug analysis of >200 compounds using MRM Spectrum mode by LC-MS/MS

Conclusions

- To reduce false negative and false positive reporting a higher number of MRM transitions were used for each veterinary drug target to increase the level of confidence in compound identification and verification. The number of fragment ion transitions monitored for each target pesticide was dependent upon the chemical structure with typically more than 10 fragment ions for each compound. MRM Spectrum mode combines conventional MRM quantitation with the generation of a high quality MRM product ion spectrum which can be used in routine library searching and compound verification and identification.
- MRM Spectrum mode was used to quantify and identify 212 drugs (the method included 2,009 MRM transitions) without compromising limits of detection, linearity or repeatability compared to a conventional 2MRM method.

First Edition: June, 2017



Shimadzu Corporation
www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affiliates, whether or not they are used with trademark symbol "TM" or "®".

Third-party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®".

Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.